You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The European Commission will now consider CHMP's opinion and decide whether to approve the regimen as a first-line option for metastatic NSCLC patients without EGFR or ALK alterations.
The European Commission will now consider whether to grant marketing authorization to the drug regimen.
The drug, which has already been approved for marketing in the US and Japan, will now be reviewed by for potential approval in the European Union.
